- Home
- LUCD vs MIST Comparison
LUCD vs MIST Comparison
Compare LUCD & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | MIST |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Canada |
| Employees | 82 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 176.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LUCD | MIST |
|---|---|---|
| Price | $1.02 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.13 | ★ $8.00 |
| AVG Volume (30 Days) | 901.2K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | $2,915.14 |
| Revenue Next Year | $130.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.90 | $1.00 |
| 52 Week High | $1.70 | $3.06 |
Technical Indicators
Market Signals| Indicator | LUCD | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 37.56 |
| Support Level | N/A | $1.00 |
| Resistance Level | $1.12 | $2.01 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 50.00 | 18.03 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).